

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

MERUS LABS INTERNATIONAL INC. (the "Company")

Suite 1820 – 925 West Georgia Street
Vancouver, British Columbia V6C 3I2
Tel: (606) 632-1700 Fax (604) 632-1730

Item 2: Date of Material Change

September 16, 2010

Item 3: News Release

The news release was disseminated on September 16, 2010 by way of CNW Group's Investment Disclosure Bundle.

Item 4: Summary of Material Change

The Company is pleased to announce that on Thursday, September 16, 2010, the Company's shares will begin trading on the Canadian National Stock Exchange under the trading symbol MR.

Item 5: Full Description of Material Change

- See attached news release.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None

Item 8: Executive Officer

For further information, please contact:

Ahmad Doroudian, President and Chief Executive Officer

Telephone: (604) 805-7783

Item 9: Date of Report

September 16, 2010

Exhibit "A"

The Canadian National Stock Exchange has not approved nor disapproved the contents of this press release.

MERUS LABS INTERNATIONAL INC.

ANNOUNCES LISTING WITH THE CANADIAN NATIONAL STOCK EXCHANGE

VANCOUVER, September 15, 2010

CNSX Symbol: MR

Merus Labs International Inc. ("Merus") is pleased to announce that effective at the open of market on Thursday, September 16, 2010, Merus' shares will begin trading on the Canadian National Stock Exchange ("CNSX") under the trading symbol **MR**. The shares will be quoted on the CNSX in Canadian currency.

Merus' stock information including Bid and Ask prices will be available on the CNSX website at www.cnsx.ca.

"Listing of our shares on the CNSX is a significant achievement which will greatly facilitate our ability to reach the broader retail and institutional investors across Canada as well as significantly enhance our access to capital. On behalf of the management and the board of directors I want to thank our shareholders, partners and professional advisors for their support towards the completion of our listing on the CNSX." said Ahmad Doroudian, President and CEO.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

For further information please contact:

Ahmad Doroudian, Ph.D.
Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783
adoroudian@meruslabs.com